Partner Headlines - BMRN

  1. BioMarin Announces Two Oral and 19 Poster Presentations at the ...

    Benzinga
  2. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  3. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  4. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  5. BioMarin Receives Rare Pediatric Disease Designation From FDA ...

    Benzinga
  6. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  7. 2 DMD drugs make progress

    IBD
  8. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  9. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  10. Benzinga's Volume Movers

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  13. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  14. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  15. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  16. Benzinga's Volume Movers

    Benzinga
  17. Morning Market Gainers

    Benzinga
  18. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  19. Benzinga's Top #PreMarket Gainers

    Benzinga
  20. BIOMARIN PHARMA

    IBD
  21. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  22. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  23. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  24. Benzinga's Top Initiations

    Benzinga
  25. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  26. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  27. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  28. BIOMARIN PHARMA

    IBD
  29. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  30. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  31. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  32. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  33. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  34. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  35. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  36. BIOMARIN PHARMA

    IBD
  37. State Of The Union Lights Up Biotech

    Benzinga
  38. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  39. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  40. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  41. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  42. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  43. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  44. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  45. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  46. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  47. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  48. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  49. BioMarin buying Prosensa

    IBD
  50. Trio Of Major Deals Disclosed

    IBD
  51. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  52. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  53. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  54. Benzinga's Volume Movers

    Benzinga
  55. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  56. Stocks Hitting 52-Week Highs

    Benzinga
  57. Morning Market Movers

    Benzinga
  58. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  59. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  60. Benzinga's Top #PreMarket Gainers

    Benzinga
  61. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  62. Stocks Hitting 52-Week Highs

    Benzinga
  63. Benzinga's Top Upgrades

    Benzinga
  64. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  65. BioMarin Weathers The Storm

    Benzinga
  66. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  67. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  68. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  69. Benzinga's Top Upgrades

    Benzinga
  70. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  71. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  72. Top Trending Tickers On StockTwits For February 18

    Benzinga
  73. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  74. You Can No Longer Ignore Biotech

    GuruFocus
  75. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  76. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  77. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  78. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  79. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  80. Benzinga's Top #PreMarket Gainers

    Benzinga
  81. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  82. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  83. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  84. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  85. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  86. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  87. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  88. Roche

    IBD
  89. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  90. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  91. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  92. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  93. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  94. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  95. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  96. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  97. Benzinga's Volume Movers

    Benzinga
  98. Benzinga's Top Pre-Market Gainers

    Benzinga
  99. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  100. Benzinga's Top Pre-Market Gainers

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!